Warner Chilcott Announces 2008 Financia...( ST. DAVID'S Bermuda Jan. 28 /- Wa...),Health

ST. DAVID'S, Bermuda, Jan. 28 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) announced today a view of anticipated full year 2008 results.

Total revenues for 2008 are expected to be in the range of $935 to $945 million, with the growth primarily being driven by LOESTRIN 24 FE, DORYX, FEMCON FE, and TACLONEX. Gross profit margin, as a percentage of total revenues, is anticipated to be in the range of 80% to 81% in 2008.

Total selling, general and administrative (SG&A) expenses in 2008 are anticipated to be in the range of $228 to $237 million, which reflects the previously disclosed reduction of advertising and promotional spend due to a reduction in DTC advertising in 2008 as compared to 2007. For a detailed view of the components of SG&A please refer to the summary at the end of this press release.

Total R&D spend in 2008 is anticipated to be in the range of $57 to $60 million. Included in this amount is internal R&D expense of $54 to $57 million and anticipated potential milestone payments to third parties of $3 million.

Based on the 2008 view, GAAP net income is expected to be in the range of $118 to $128 million. Cash net income in 2008 is anticipated to be $315 to $325 million. Using 251.0 million Class A shares, the Company expects cash net income per share to be in the range of $1.25 to $1.30 for the full year 2008.

References in this press release to "cash net income" mean the Company's net income adjusted for the after-tax effects of two non-cash items: amortization of intangible assets and amortization (or write-off) of deferred loan costs related to the Company's debt. Reconciliations from the Company's anticipated US GAAP results to cash net income expected results are prese
'/>"/>